

FIBROSIS RESULTS PRESENTED AT INTERNATIONAL CONFERENCE

Melbourne, Australia, 7 November 2013: Australian biopharmaceutical company Immuron Limited (ASX: IMC), reports that its bovine colostrum derived therapeutic IMM-124E, has been presented as a potential therapeutic for fibrosis at the 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), that was convened in Washington DC between 1 – 5 November.

Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue during an inflammatory or reparative process. Fibrosis disrupts the normal function of an organ or tissue, and this is different from the formation of fibrous tissue as a normal constituent of an organ or tissue. Liver fibrosis is the common scarring reaction associated with chronic liver injury. With protracted damage, fibrosis can progress toward excessive scarring and organ failure, as in liver cirrhosis.

Based on animal studies at the Hadassah Medical Centre, Immuron's IMM-124E which contains bovine colostrum enriched with antibodies reactive to lipopolysaccharides (LPS), can be applied for the prophylaxis, treatment or alleviation of fibrosis, particularly, lung fibrosis and liver fibrosis.

The meeting was attended by approximately 10,000 people including key opinion leaders, clinicians and pharmaceutical company executives active in this field.

Immuron's Chief Executive Officer Amos Meltzer said: "Whilst the number of patients suffering from fibrosis in different organs is difficult to ascertain, the results that were presented at the AASLD support our expectation that IMM-124E is a potential therapeutic for a large range of fatty liver patients including those with fibrosis of the liver."

Contact

Amos Meltzer – Chief Executive Officer
+61 (0) 437 587 680

About Immuron Limited

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron is uniquely positioned with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and increases the prospect that the clinical development of Immuron's products will be expedited. Immuron's current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver (NASH), and the prevention of influenza. Immuron has one product in the market, Travelan, for preventing travellers' diarrhoea. Immuron's main scientific alliances are with Hadassah Medical Center (Israel) and Monash University (Australia).